Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5259824 | 0.75 | MEN1 (0.53) | ALDH1A1MAPTCYP3A4MAPK1POLB | |
| SCHEMBL1467521 | 0.72 | ALDH1A1 (0.48) | ALDH1A1MAPTCYP3A4MAPK1POLB | |
| SCHEMBL4991868 | 0.71 | ACHE (0.44) | ALDH1A1MAPTCYP3A4MAPK1POLB | |
| SCHEMBL4068852 | 0.70 | CYP2D6 (0.43) | ALDH1A1MAPTCYP2D6CA1CA2 | |
| SCHEMBL1467603 | 0.70 | MAPT (0.52) | ALDH1A1MAPTCYP3A4MAPK1POLB | |
| SCHEMBL4328031 | 0.67 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1POLBMEN1 | |
| SCHEMBL9313173 | 0.67 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1POLBMEN1 | |
| SCHEMBL2122579 | 0.67 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1POLBMEN1 | |
| SCHEMBL22742 | 0.67 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1POLBMEN1 | |
| SCHEMBL10869745 | 0.67 | ALDH1A1 (0.68) | ALDH1A1CYP3A4MAPK1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| US-8394836-B2 | Indoles and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| EP-2327693-A1 | Indoles and their therapeutic use | Pulmagen Therapeutics (Asthma) Limited (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | GB005, INC. | 2011-03-24 | — | — | US | disclosed |
| EP-2229358-A1 | INDOLES AND THEIR THERAPEUTIC USE | Pulmagen Therapeutics (Asthma) Limited (GB) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077728-A1 | INDOLES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225617-A1 | INDOLES AND THEIR THERAPEUTIC USE | IDO2, IDO1, RORB | ALDH1A1 1047/4885MAPT 3223/4885CYP3A4 2537/4885 |
| US-20110071175-A1 | Indoles and Their Therapeutic Use | FPR3, HRH2, HRH4 | ALDH1A1 1510/4885MAPT 4666/4885CYP3A4 1973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.